FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2255704573> ?p ?o ?g. }

• W2255704573 endingPage "e14669" @default.
• W2255704573 startingPage "e14669" @default.
• W2255704573 abstract "e14669 Background: Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma (HCC) in randomized phase III trials. The efficacy and safety of sorafenib in the treatment of recurrent HCC after liver transplantation, however, has not been determined. Methods: We retrospectively analyzed 13 patients who were treated with sorafenib for recurrent HCC after liver transplantation. Results: All 13 patients underwent living-donor liver transplantation for HCC with underlying liver cirrhosis caused by hepatitis B virus (HBV) infection. The median model for end-stage liver disease (MELD) score at transplantation was 7.6 (range, 4.2-25.2). The median time from liver transplantation to detection of recurrent HCC was 12.3 months (range, 0.5-33.4 months). The median serum alpha-fetoprotein (AFP) concentration before sorafenib administration was 193 ng/mL (range, 1-20,500 ng/mL). Eleven of 13 patients had a starting dose of 400mg twice daily and two had a starting dose of 200 mg twice daily at the discretion of the attending physician. The median duration of sorafenib treatment was 2.4 months (range, 0.3-9.9 months). Single or multiple immunosuppressants were coadministered in these patients during sorafenib treatment. Six of 10 evaluable patients showed stable disease, which was the best response and the median duration of stabilization was 3.9 months (95% confidence interval [CI], 1.6–6.2 months). At a median follow-up duration of 3.7 months (range, 0.3-10.9 months) in living patients, the median progression-free survival and the median overall survival from commencement of sorafenib were 2.9 months (95% CI, 1.2-4.6 months) and 5.4 months (95% CI, 3.7-7.0 months), respectively. Grade 3 neutropenia was observed in one patient, which was the only high grade hematologic toxicity observed. Grade 3 hand-foot skin reactions were observed in three patients. Adverse events could be managed with dose adjustment. Conclusions: These findings suggest that the efficacy of sorafenib for recurrent HCC after liver transplantation may not be inferior to that observed in phase 3 trials conducted in non- transplant patients and the drug may be safely administered with careful monitoring in these patients. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer Bayer" @default.
• W2255704573 created "2016-06-24" @default.
• W2255704573 creator A5014101324 @default.
• W2255704573 creator A5019279392 @default.
• W2255704573 creator A5028088359 @default.
• W2255704573 creator A5034463208 @default.
• W2255704573 creator A5035518428 @default.
• W2255704573 creator A5036086195 @default.
• W2255704573 creator A5050625196 @default.
• W2255704573 creator A5053179392 @default.
• W2255704573 creator A5058616076 @default.
• W2255704573 creator A5059231924 @default.
• W2255704573 date "2010-05-20" @default.
• W2255704573 modified "2023-09-26" @default.
• W2255704573 title "Sorafenib for recurrent hepatocellular carcinoma after liver transplantation." @default.
• W2255704573 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e14669" @default.
• W2255704573 hasPublicationYear "2010" @default.
• W2255704573 type Work @default.
• W2255704573 sameAs 2255704573 @default.
• W2255704573 citedByCount "0" @default.
• W2255704573 crossrefType "journal-article" @default.
• W2255704573 hasAuthorship W2255704573A5014101324 @default.
• W2255704573 hasAuthorship W2255704573A5019279392 @default.
• W2255704573 hasAuthorship W2255704573A5028088359 @default.
• W2255704573 hasAuthorship W2255704573A5034463208 @default.
• W2255704573 hasAuthorship W2255704573A5035518428 @default.
• W2255704573 hasAuthorship W2255704573A5036086195 @default.
• W2255704573 hasAuthorship W2255704573A5050625196 @default.
• W2255704573 hasAuthorship W2255704573A5053179392 @default.
• W2255704573 hasAuthorship W2255704573A5058616076 @default.
• W2255704573 hasAuthorship W2255704573A5059231924 @default.
• W2255704573 hasConcept C126322002 @default.
• W2255704573 hasConcept C141071460 @default.
• W2255704573 hasConcept C2776455275 @default.
• W2255704573 hasConcept C2777075537 @default.
• W2255704573 hasConcept C2777214474 @default.
• W2255704573 hasConcept C2778019345 @default.
• W2255704573 hasConcept C2778695046 @default.
• W2255704573 hasConcept C2779609443 @default.
• W2255704573 hasConcept C2911091166 @default.
• W2255704573 hasConcept C71924100 @default.
• W2255704573 hasConcept C90924648 @default.
• W2255704573 hasConceptScore W2255704573C126322002 @default.
• W2255704573 hasConceptScore W2255704573C141071460 @default.
• W2255704573 hasConceptScore W2255704573C2776455275 @default.
• W2255704573 hasConceptScore W2255704573C2777075537 @default.
• W2255704573 hasConceptScore W2255704573C2777214474 @default.
• W2255704573 hasConceptScore W2255704573C2778019345 @default.
• W2255704573 hasConceptScore W2255704573C2778695046 @default.
• W2255704573 hasConceptScore W2255704573C2779609443 @default.
• W2255704573 hasConceptScore W2255704573C2911091166 @default.
• W2255704573 hasConceptScore W2255704573C71924100 @default.
• W2255704573 hasConceptScore W2255704573C90924648 @default.
• W2255704573 hasIssue "15_suppl" @default.
• W2255704573 hasLocation W22557045731 @default.
• W2255704573 hasOpenAccess W2255704573 @default.
• W2255704573 hasPrimaryLocation W22557045731 @default.
• W2255704573 hasRelatedWork W1422039816 @default.
• W2255704573 hasRelatedWork W1965887611 @default.
• W2255704573 hasRelatedWork W2054405008 @default.
• W2255704573 hasRelatedWork W2148441798 @default.
• W2255704573 hasRelatedWork W2255318257 @default.
• W2255704573 hasRelatedWork W2770607349 @default.
• W2255704573 hasRelatedWork W2892133880 @default.
• W2255704573 hasRelatedWork W29557401 @default.
• W2255704573 hasRelatedWork W3197598734 @default.
• W2255704573 hasRelatedWork W4210912349 @default.
• W2255704573 hasVolume "28" @default.
• W2255704573 isParatext "false" @default.
• W2255704573 isRetracted "false" @default.
• W2255704573 magId "2255704573" @default.
• W2255704573 workType "article" @default.